CJC-1295 (with DAC)
Overview
Research-use GHRH analogue with DAC modification supplied for studies of sustained somatotropic-axis signaling models.
- Concentration
- 5 mg
- Stock
- In stock
Product details
CJC-1295 with DAC is a modified GHRH analogue used in research models of sustained somatotropic-axis signaling. Pattern lists this material for controlled laboratory research.
Research Targets: GHRH receptor signaling, albumin-binding pharmacokinetic models, pituitary somatotroph pathways.
Key Feature: DAC modification designed for extended experimental exposure windows.
Research Focus Areas: Somatotroph stimulation, GH/IGF-1 pathway signaling, endocrine feedback modeling, pharmacokinetic study designs.
Common Models: Pituitary cell assays, rodent endocrine models, receptor-signaling experiments.
Mechanistic Interests: GHRH receptor activation, cAMP/PKA signaling, albumin-binding kinetics, downstream IGF-1 pathway markers.
Use Boundary: Research use only; not for human or veterinary use; no diagnostic, therapeutic, or consumption use is implied.
Product documentation
Certificate of Analysis
CJC-1295 with DAC
Review the public certificate available for this product before creating an account or checking out.
Research context
Peptide guide
Open full guide- Guide profile
- Growth Hormone-Releasing Hormone Analog
- Composition
- Synthetic analog of growth hormone-releasing hormone (GHRH), consisting of 30 amino acids with modifications for enhanced stability and prolonged activity
- Discovery
- Developed by ConjuChem Biotechnologies in the early 2000s as a long-acting GHRH analog, incorporating amino acid substitutions for resistance to degradation and (in the DAC form) an albumin-binding moiety to extend circulation time
- Research scope
- Human evidence is centered on small early studies of CJC-1295 with DAC and broader growth-hormone secretagogue physiology.
- Regulatory status
- Not approved for medical use; off-label exploration focuses on body composition and recovery
Safety context
- Limited data; avoid in active cancer
- Diabetes without oversight
- Pituitary issues
Research-use notice: CJC-1295 can raise GH/IGF-1 in early human studies, especially in DAC-linked form, but clinical outcome evidence remains limited. It is not FDA-approved, and claims about recovery, body composition, performance, or longevity are not established by large trials. Use decisions require qualified medical oversight and monitoring.
Full guide includes 10 reference entries.
One kit adds 10 vials to WooCommerce checkout.